Zacks: Analysts Anticipate La Jolla Pharmaceutical (LJPC) to Post -$1.25 Earnings Per Share

Equities analysts expect La Jolla Pharmaceutical (NASDAQ:LJPC) to report ($1.25) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for La Jolla Pharmaceutical’s earnings. The highest EPS estimate is ($1.10) and the lowest is ($1.38). La Jolla Pharmaceutical reported earnings of ($1.44) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 13.2%. The firm is expected to issue its next earnings results on Thursday, February 22nd.

On average, analysts expect that La Jolla Pharmaceutical will report full-year earnings of ($4.91) per share for the current year, with EPS estimates ranging from ($5.05) to ($4.74). For the next fiscal year, analysts anticipate that the company will report earnings of ($4.46) per share, with EPS estimates ranging from ($5.45) to ($3.10). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow La Jolla Pharmaceutical.

A number of equities analysts have weighed in on LJPC shares. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research report on Wednesday, November 1st. Cowen reiterated a “buy” rating and set a $55.00 target price on shares of La Jolla Pharmaceutical in a research report on Friday, October 27th. HC Wainwright started coverage on shares of La Jolla Pharmaceutical in a research report on Thursday, December 21st. They set a “buy” rating and a $62.00 target price for the company. Chardan Capital reiterated a “buy” rating and set a $90.00 target price on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. Finally, SunTrust Banks reiterated a “buy” rating and set a $65.00 target price (down previously from $67.00) on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $57.00.

In other news, major shareholder Life Sciences Maste Perceptive acquired 175,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The stock was bought at an average cost of $32.72 per share, for a total transaction of $5,726,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Laura L. Douglass sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $32.32, for a total transaction of $323,200.00. The disclosure for this sale can be found here. Insiders have acquired 177,000 shares of company stock valued at $5,792,440 in the last quarter. Company insiders own 25.47% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in LJPC. Schwab Charles Investment Management Inc. boosted its position in shares of La Jolla Pharmaceutical by 30.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 28,079 shares of the biopharmaceutical company’s stock valued at $836,000 after acquiring an additional 6,500 shares during the period. Wells Fargo & Company MN boosted its position in shares of La Jolla Pharmaceutical by 23.0% in the second quarter. Wells Fargo & Company MN now owns 16,937 shares of the biopharmaceutical company’s stock valued at $504,000 after acquiring an additional 3,167 shares during the period. Alliancebernstein L.P. boosted its position in shares of La Jolla Pharmaceutical by 34.6% in the second quarter. Alliancebernstein L.P. now owns 17,100 shares of the biopharmaceutical company’s stock valued at $509,000 after acquiring an additional 4,400 shares during the period. Teachers Advisors LLC boosted its position in shares of La Jolla Pharmaceutical by 21.5% in the second quarter. Teachers Advisors LLC now owns 30,859 shares of the biopharmaceutical company’s stock valued at $919,000 after acquiring an additional 5,469 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its position in La Jolla Pharmaceutical by 29.5% during the second quarter. TIAA CREF Investment Management LLC now owns 47,043 shares of the biopharmaceutical company’s stock valued at $1,400,000 after purchasing an additional 10,703 shares during the last quarter.

Shares of La Jolla Pharmaceutical (NASDAQ LJPC) traded up $0.91 during trading hours on Monday, reaching $33.87. 452,090 shares of the company’s stock were exchanged, compared to its average volume of 508,692. The company has a market capitalization of $750.06, a price-to-earnings ratio of -6.64 and a beta of 1.20. La Jolla Pharmaceutical has a 12-month low of $16.71 and a 12-month high of $41.36.

COPYRIGHT VIOLATION NOTICE: This article was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://stocknewstimes.com/2018/02/19/zacks-analysts-anticipate-la-jolla-pharmaceutical-ljpc-to-post-1-25-earnings-per-share.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Get a free copy of the Zacks research report on La Jolla Pharmaceutical (LJPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply